Intravenous versus Oral Step-Down for the Treatment of Staphylococcus aureus Bacteremia in a Pediatric Population

Limited data are available regarding optimal antimicrobial therapy for Staphylococcus aureus bacteremia (SAB) in pediatric patients. The purpose of this study was to assess clinical characteristics and outcomes associated with intravenous (IV) versus oral step-down treatment of pediatric SAB. This study evaluated patients aged 3 months to 18 years that received at least 72 h of inpatient treatment for SAB. The primary endpoint was 30-day readmission. Secondary endpoints included hospital length of stay and inpatient mortality. One hundred and one patients were included in this study. The median age was 7.9 years. Patients who underwent oral step-down were less likely to be immunocompromised and more likely to have community-acquired SAB from osteomyelitis or skin and soft tissue infection (SSTI). More patients in the IV therapy group had a 30-day readmission (10 (25.6%) vs. 3 (5.3%), p = 0.006). Mortality was low (5 (5%)) and not statistically different between groups. Length of stay was greater in patients receiving IV therapy only (11 vs. 7 days, p = 0.001). In this study, over half of the patients received oral step-down therapy and 30-day readmission was low for this group. Oral therapy appears to be safe and effective for patients with SAB from osteomyelitis or SSTIs.

Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin 1-beta?

Cefazolin and ertapenem has been shown to be an effective salvage regimen for refractory methicillin-susceptible Staphylococcus aureus bacteremia. Our findings suggest cefazolin plus ertapenem in vitro stimulates interleukin-1β release from peripheral blood monocytes both with and without S. aureus presence. This IL-1β augmentation was primarily driven by ertapenem. These findings support further exploration of cefazolin plus ertapenem in MSSA bacteremia and may partially explain its marked potency in vivo despite modest synergy in vitro .

Comparison of Staphylococcus Aureus Endocarditis Risk Factors With Bacteremia

Introduction: Infective endocarditis (IE) is endothelial damage of the endocardium, which is caused by infection. The etiologic agents' highest mortality and morbidity rates are associated with staphylococcus aureus (S. aureus). Accordingly, the knowledge of different risk factors for IE caused by the S. aureus is necessary.Material and methods: This study is an observational-analytical retrospective cohort study on 139 patients with staphylococcus aureus bacteremia (SAB), who referred to a cardiac center during 2011-2019. This study aimed to evaluate the risk factors in 48 patients with staphylococcus aureus endocarditis, who were selected from139 patients with S. aureus bacteremia. Results: The mean age (±SD) of the patients is 56.61 (±16.58), and85 (61.2%) persons are male. Forty-eight patients (34.5%) are diagnosed with staphylococcus aureus endocarditis regarding Duke criteria. In this study, the following risk factors were significantly associated with S. aureus endocarditis: age (p=0.003), long-term bacteremia (p=0.041), prosthetic heart valve (p=0.016), pre-existing IE (p=0.048), and embolic events (p=0.039).Conclusion: According to the findings, a significant number of patients with staphylococcus aureus bacteremia (SAB) have IE with different risk factors. Future studies with a larger sample size are recommended to detect IE risk factors.